PE99699A1 - Composicion que comprende un inhibidor selectivo de la reabsorcion de serotonina y un �-bloqueante - Google Patents

Composicion que comprende un inhibidor selectivo de la reabsorcion de serotonina y un �-bloqueante

Info

Publication number: PE99699A1
Authority: PE; Peru
Prior art keywords: selective inhibitor; blocker; composition including; serotonin reabsorption; composition
Prior art date: 1997-07-11

Application number

PE1998000612A

Other languages

English (en)

Spanish (es)

Inventor

Paul John Cummings

Ian Frederic Tulloch

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-11

Filing date

1998-07-10

Publication date

1999-12-21

1998-07-10 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

1999-12-21 Publication of PE99699A1 publication Critical patent/PE99699A1/es

Links

QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title abstract 4
229940124639 Selective inhibitor Drugs 0.000 title abstract 2
230000009103 reabsorption Effects 0.000 title abstract 2
229940076279 serotonin Drugs 0.000 title abstract 2
AHOUBRCZNHFOSL-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine Chemical compound C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 abstract 4
208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 2
229960005183 paroxetine hydrochloride Drugs 0.000 abstract 2
PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 abstract 2
229960002508 pindolol Drugs 0.000 abstract 2
208000007848 Alcoholism Diseases 0.000 abstract 1
208000024827 Alzheimer disease Diseases 0.000 abstract 1
208000019901 Anxiety disease Diseases 0.000 abstract 1
208000000094 Chronic Pain Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
206010039966 Senile dementia Diseases 0.000 abstract 1
201000007930 alcohol dependence Diseases 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
208000019906 panic disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Epidemiology (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

PE1998000612A 1997-07-11 1998-07-10 Composicion que comprende un inhibidor selectivo de la reabsorcion de serotonina y un �-bloqueante PE99699A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9714675.7A GB9714675D0 (en)	1997-07-11	1997-07-11	Novel composition

Publications (1)

Publication Number	Publication Date
PE99699A1 true PE99699A1 (es)	1999-12-21

Family

ID=10815744

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE1998000612A PE99699A1 (es)	1997-07-11	1998-07-10	Composicion que comprende un inhibidor selectivo de la reabsorcion de serotonina y un �-bloqueante

Country Status (26)

Country	Link
EP (1)	EP0996466A2 (id)
JP (1)	JP2002508003A (id)
KR (1)	KR20010021644A (id)
CN (1)	CN1262627A (id)
AP (1)	AP2000001728A0 (id)
AR (1)	AR016128A1 (id)
AU (1)	AU9340198A (id)
BG (1)	BG104119A (id)
BR (1)	BR9810996A (id)
CA (1)	CA2295822A1 (id)
CO (1)	CO4950552A1 (id)
DZ (1)	DZ2556A1 (id)
EA (1)	EA200000112A1 (id)
GB (1)	GB9714675D0 (id)
HU (1)	HUP0003074A3 (id)
ID (1)	ID24191A (id)
IL (1)	IL133869A0 (id)
MA (1)	MA24604A1 (id)
NO (1)	NO20000107L (id)
OA (1)	OA11276A (id)
PE (1)	PE99699A1 (id)
PL (1)	PL338017A1 (id)
SK (1)	SK72000A3 (id)
TR (1)	TR200000074T2 (id)
WO (1)	WO1999002142A2 (id)
ZA (1)	ZA986138B (id)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69942009D1 (de)	1998-10-15	2010-03-25	Imp Innovations Ltd	Verbindungen für die behandlung von gewichtsverlust
IL142896A0 (en)	1998-11-02	2002-04-21	Elan Corp Plc	Multiparticulate modified release composition
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
EP2295043A1 (en)	1999-10-29	2011-03-16	Euro-Celtique S.A.	Controlled release hydrocodone formulations
GB0004003D0 (en) *	2000-02-22	2000-04-12	Knoll Ag	Therapeutic agents
AU2002227383B2 (en)	2000-10-30	2004-07-08	Euro-Celtique S.A.	Controlled release hydrocodone formulations
WO2006030306A2 (en) *	2004-09-17	2006-03-23	Neurocure Ltd	Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder
CN100469356C (zh) *	2006-09-08	2009-03-18	山东益康药业有限公司	复方阿替洛尔缓释片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2732335C2 (de) *	1976-07-27	1983-01-20	Sandoz-Patent-GmbH, 7850 Lörrach	Tablette zur enteralen Verabreichung von Indolyloxyalkanolamin-Derivaten
CA2134038C (en) *	1994-06-16	1997-06-03	David Taiwai Wong	Potentiation of drug response
EP0714663A3 (en) *	1994-11-28	1997-01-15	Lilly Co Eli	Potentiation of drug responses by serotonin 1A receptor antagonists
PT759299E (pt) *	1995-08-16	2000-09-29	Lilly Co Eli	Potenciacao da resposta de serotonina
EP0792649A1 (en) *	1996-02-29	1997-09-03	Eli Lilly And Company	Treatment of sleep disorders

1997
- 1997-07-11 GB GBGB9714675.7A patent/GB9714675D0/en active Pending
1998
- 1998-07-07 ID IDW20000035A patent/ID24191A/id unknown
- 1998-07-07 EA EA200000112A patent/EA200000112A1/ru unknown
- 1998-07-07 PL PL98338017A patent/PL338017A1/xx unknown
- 1998-07-07 TR TR2000/00074T patent/TR200000074T2/xx unknown
- 1998-07-07 SK SK7-2000A patent/SK72000A3/sk unknown
- 1998-07-07 EP EP98946294A patent/EP0996466A2/en not_active Withdrawn
- 1998-07-07 HU HU0003074A patent/HUP0003074A3/hu unknown
- 1998-07-07 JP JP50818599A patent/JP2002508003A/ja active Pending
- 1998-07-07 AU AU93401/98A patent/AU9340198A/en not_active Abandoned
- 1998-07-07 WO PCT/EP1998/004971 patent/WO1999002142A2/en not_active Ceased
- 1998-07-07 CN CN98806975A patent/CN1262627A/zh active Pending
- 1998-07-07 BR BR9810996-0A patent/BR9810996A/pt not_active Application Discontinuation
- 1998-07-07 AP APAP/P/1999/001728A patent/AP2000001728A0/en unknown
- 1998-07-07 IL IL13386998A patent/IL133869A0/xx unknown
- 1998-07-07 CA CA002295822A patent/CA2295822A1/en not_active Abandoned
- 1998-07-07 KR KR1020007000202A patent/KR20010021644A/ko not_active Withdrawn
- 1998-07-08 DZ DZ980166A patent/DZ2556A1/xx active
- 1998-07-10 AR ARP980103371A patent/AR016128A1/es unknown
- 1998-07-10 CO CO98039260A patent/CO4950552A1/es unknown
- 1998-07-10 ZA ZA9806138A patent/ZA986138B/xx unknown
- 1998-07-10 PE PE1998000612A patent/PE99699A1/es not_active Application Discontinuation
- 1998-07-10 MA MA25165A patent/MA24604A1/fr unknown
2000
- 2000-01-10 NO NO20000107A patent/NO20000107L/no not_active Application Discontinuation
- 2000-01-11 OA OA1200000006A patent/OA11276A/en unknown
- 2000-02-01 BG BG104119A patent/BG104119A/xx unknown

Also Published As

Publication number	Publication date
OA11276A (en)	2003-07-31
HUP0003074A3 (en)	2001-12-28
EA200000112A1 (ru)	2000-10-30
BR9810996A (pt)	2000-08-08
AU9340198A (en)	1999-02-08
HUP0003074A2 (hu)	2001-01-29
CA2295822A1 (en)	1999-01-21
ID24191A (id)	2000-07-13
TR200000074T2 (tr)	2000-05-22
CO4950552A1 (es)	2000-09-01
WO1999002142A2 (en)	1999-01-21
PL338017A1 (en)	2000-09-25
WO1999002142A3 (en)	1999-04-15
ZA986138B (en)	2000-01-10
CN1262627A (zh)	2000-08-09
JP2002508003A (ja)	2002-03-12
BG104119A (en)	2000-12-29
EP0996466A2 (en)	2000-05-03
NO20000107D0 (no)	2000-01-10
SK72000A3 (en)	2000-12-11
NO20000107L (no)	2000-01-10
MA24604A1 (fr)	1999-04-01
KR20010021644A (ko)	2001-03-15
GB9714675D0 (en)	1997-09-17
DZ2556A1 (fr)	2003-02-15
AP2000001728A0 (en)	2000-03-31
IL133869A0 (en)	2001-04-30
AR016128A1 (es)	2001-06-20

Legal Events

Date	Code	Title	Description
2001-08-28	FC	Refusal

Publication	Publication Date	Title
CO4900058A1 (es)	2000-03-27	Terapia de combinacion para el tratamiento de psicosis
Calabrese et al.	2007	Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data
Papp et al.	2002	Behavioural and biochemical studies of citalopram and WAY 100635 in rat chronic mild stress model
Sanchez-Mateo et al.	2002	Antidepressant effects of the methanol extract of several Hypericum species from the Canary Islands
NO20054228L (no)	2005-09-12	Anvendelse av (IS,2R)-enantiomeren av milnacipran for fremstillingen av et medikament
ES2153410T3 (es)	2001-03-01	Elemento aislante de pared, piso o fachada y sistema para renovacion de aire.
ATE319464T1 (de)	2006-03-15	Diätetische nahrungsergänzung zur unterstützung des zerebrovaskulären tonus
BRPI0509461A (pt)	2007-09-04	implantes intravìtreos compreendendo microesferas que encapsulam um inibidor de tirosina cinase e um polìmero biodegradável
MY152919A (en)	2014-12-15	Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
YU56301A (sh)	2004-05-12	Inhibitori resorpcije monoamina za tretiranje poremećaja cns
De Witte	2016	Encountering religion through Accra’s urban soundscape
DE602005003343D1 (de)	2007-12-27	Arzneiimittel mit verdecktem geschmack in aufbrechenden multipartikeln
JP2008013542A5 (id)	2010-06-24
BRPI0411665A (pt)	2006-08-08	uso de agomelatina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica ou kit, e, métodos para o tratamento de doenças ou distúrbios responsivos a um inibidor da recaptação de serotonina e para aumentar e/ou proporcionar inìcio mais rápido do efeito terapêutico de um inibidor da recaptação de serotonina
Freudenmann et al.	2004	The Neuropsychopharmacology and Toxicology of 3, 4‐methylenedioxy‐N‐ethyl‐amphetamine (MDEA)
JP2007505156A5 (id)	2007-07-05
AR017884A1 (es)	2001-10-24	Proceso para preparar una composicion farmaceutica que comprende zafirlukast, dicha composicion farmaceutica y metodo para tratar pacientes usando lacomposicion
TW200507846A (en)	2005-03-01	Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
CO4950552A1 (es)	2000-09-01	Nueva composicion lectivos de la reabsorcion de seotonina y un bloqueador b
Martínez-Mota et al.	2005	Ejaculation induces long-lasting behavioural changes in male rats in the forced swimming test: evidence for an increased sensitivity to the antidepressant desipramine
Parrott	2003	Cognitive deficits and cognitive normality in recreational cannabis and Ecstasy/MDMA users.
ATE506348T1 (de)	2011-05-15	Neue benzoylpiperidinverbindungen
Meltzer et al.	2004	Addition of ibuprofen to pseudoephedrine and chlorpheniramine in the treatment of seasonal allergic rhinitis
Kadioglu et al.	2010	Paroxetine inhibited the relaxations induced by EFS in mice corpus cavernosum: is it a NOS inhibition?
Jefferies	2022	AISLINGE MEIC CON GLINNE—AN EARLY MEDIEVAL ‘VISION’OF CORK